Relmada Therapeutics Inc. (NASDAQ:RLMD) currently has a daily average trading volume of 1.04M but it saw 419898 shares traded on Wednesday. With a market cap of 159.60M USD, stock’s current market price of $5.25 came falling about -7.08 while comparing to the previous closing price of $5.65. In past 52 weeks, the stock remained buoying in the range of price level as high as $38.68 and as low as $5.46. In the recent trading on the day, stock has struck highest price mark of $5.74 while lowest mark touched by it was $5.22.
Taking a look at 20-day trading activity of Relmada Therapeutics Inc. (RLMD) gives us an average price of $6.08, while its current price level is -86.43% below from 52-week high level whereas it is -3.85% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $17.23 while that of 200 days or SMA-200 reads an average of $21.85. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.11% during that period while stretching the period over a month that increases to 8.47%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 24.17 which implies that the stock is in oversold territory.
The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $6.50 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $42.00. Average price target assigned by them is $17.42 which highlights an upside potential of 69.86% for the stock over that period. And to attain the median price target of $7.50 assigned by those analysts, stock has to add about 30.0% of value to its current levels.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Truist which downgraded the stock as “Hold” in its note to investors issued on October 14, 2022, recommending a price target of between $90 and $10 for it. Goldman also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $81 and $8.
Over the week, RLMD’s stock price is moving -9.17% down while it is -26.06% when we observe its performance for the past one month. Year-to-date it is -76.70% down and over the past year, the stock is showing a downside performance of -72.37%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$1.33 beaten by the consensus estimate of -$1.27 for the same. For RLMD, analysts are forecasting an EPS-growth rate of 21.60% for current year and estimate for EPS growth in next year is 31.00%.
Currently, Relmada Therapeutics Inc.’s total number of outstanding shares is 30.06M with 1.29% of that held by the insiders while 100.57% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -78.50%. Stock’s beta reads 0.07. Stock has a price to book (P/B) ratio of 0.95. Its return on asset (ROA) is -72.10% on average.
As per SEC documents, Vanguard Total Stock Market Index shunned 904,705 of company’s common stock of worth $5.78 million as per recent closing price of the stock. Vanguard Total Stock Market Index is not the only institutional holder which restructured its stake in Relmada Therapeutics Inc., as iShares Russell 2000 ETF dumped 602,907 shares of worth $3.85 million to bring its holdings to a total of 11235.0 shares. In the most recent quarter, Vanguard Extended Market Index Fu came rising its stake by 0.38% in the company and now holds 0.35 million or 1.18% of the company’s stake having worth of about 2.26 million.